Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab with or without Balstilimab in Advanced Melanoma Refractory to Checkpoint Inhibitors
NCT05529316Phase 2Terminated
- Sponsor
- Agenus Inc.
- Start
- Dec 2022
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of botensilimab in melanoma, sponsored by Agenus Inc.. Started Dec 2022; status: terminated.
02
Drugs
botensilimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05529316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05529316.